Luc Maruenda joined Idinvest Partners in 1999, and is Partner in charge of the structuring, development and commercialization of Idinvest’s private asset management products, whilst also maintaining a role as Venture Capital investor, notably with regard to the monitoring of his investments. As the head of the Private Client Solutions department, since 1999, Luc has developed Idinvest’s private asset management offer so as to provide adapted solutions to the demands and constraints of French (and European) private investors: firstly with FCPIs, then with the development of new products offering asset diversification solutions on the different investment strategies deployed by Idinvest. Prior to joining Idinvest, Luc took part in the launch of a private equity program in the United Arab Emirates, where he took joint responsibility for the venture capital investments of The National Investor in Abu Dhabi. Before that, Luc was investment director in the offset team at Giat Industries (Nexter Group) in Abu Dhabi. Prior to that, he was CFO of the start-up Webcorp in San Francisco and worked as audit manager at Cabinet Constantin in Paris and then in New York for three years. Luc trained as an expert-comptable (chartered accountant equivalent) and holds a Master’s degree in Business Law.
Valéry Huot, Managing Partner of Innovation Capital since 2004, joined LBO France in 2016 when the two companies merged. He has been involved in many trade sales and IPOs (Novaled, Aldebaran Robotics, RSI Video Systems, eFront, Anevia, Doubletrade, Netcentrex…) and sits at the board of several ongoing investments (BIOMODEX, BioSerenity, H4D, OpenHealth and Wandercraft). He started his career in Australia in a joint research lab between Telstra and Sydney Uni, then worked at the French Defense Procurement Agency and later at the French Treasury in charge of SMEs financing and innovation politics. He then co-led in 2001 the fund of fund activity of CDC Enterprises. Valéry graduated from Stanford University and Ecole Polytechnique.
François Thomas is chairman of the Board at BIOMODEX since 2019. He is specialized in biotechnology, business development, venture capital, medical oncology and drug development. He is the head of the Inserm Transfert Initiative portfolio, managed since September 2017 by Sofimac Innovation. Director of Therachon, then censor (2015-2018), Annapurna (2015-2016, until the merger with Avalanche listed on NASDAQ), Enyo (censor since 2015), Step Pharma, Eyevensys, AelisFarma, BIOMODEX, Sensorion (2015 -2019), Censor of Inotrem (2015-2019). François studied oncology in France and also holds a master’s degree in management from Massachusetts Institute of Technology (MIT) – Sloan School of Management.